Den Europæiske Union - dansk - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - bryst neoplasmer - antineoplastiske midler - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

towa pharmaceutical europe, s.l. - dabigatranetexilatmesilat - kapsler, hårde - 150 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - dabigatranetexilatmesilat - kapsler, hårde - 110 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

biomarin international limited - valoctocogene roxaparvovec - antihemorrhagics - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

rotterdam biologics b.v. - bevacizumab - wet macular degeneration - oftalmologiske - treatment of neovascular (wet) age-related macular degeneration (amd).